# Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients

> **NCT07673861** · NA · RECRUITING · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Gastrointestinal Stromal Tumor (GIST)
- Colorectal Cancer
- Biliary Tract Cancer
- Ovarian Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Marsden360 ctDNA test and GTAB review

## Key facts

- **NCT ID:** NCT07673861
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-23
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673861, "Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*